My ePortfolio Register   

Phase III trial data supports current standard 12-month adjuvant trastuzumab for HER2-positive breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.12.17
Views: 133
Rating:

Prof Heikki Joensuu - University of Helsinki, Helsinki, Finland

Prof Joensuu speaks at a SABCS 2017 press session about data from the phase III Synergism or Long Duration (SOLD) clinical trial.

Disease-free survival (DFS) after nine weeks of adjuvant trastuzumab and standard chemotherapy was not comparable to DFS after 12 months of adjuvant trastuzumab and standard chemotherapy for women with early-stage HER2-positive breast cancer, supporting the current practice of extended trastuzumab treatment.

Read the news story for more.

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence